UHS(US:UHS)2026-02-26 15:00Financial Data and Key Metrics Changes - Revenue growth for Q4 2025 was 9%, with adjusted EBITDA net of NCI increasing by 10% and adjusted EPS rising by 20% compared to Q4 2024 [4] - For the full year 2025, revenue growth was 10%, adjusted EBITDA net of NCI increased by 15%, and adjusted EPS grew by 31% [4][10] - Net income attributable to UHS per diluted share for Q4 2025 was $7.06, with adjusted net income per diluted share at $5.88 [10] Business Line Data and Key Metrics Changes - In the acute care segment, same-facility net revenues increased by 6.9% in Q4 2025, with same-facility revenue per adjusted admission rising by 5.4% [11] - The behavioral health segment saw same-facility net revenues increase by 7.2%, supported by a 5.6% increase in same-facility revenue per adjusted patient day [13] - Acute care segment EBITDA margin improved by 50 basis points to 14.8% in Q4 2025, while the full year margin improved by 150 basis points to 15.8% [12] Market Data and Key Metrics Changes - Acute care volumes were flat in Q4 2025, impacted by softness in the Las Vegas market, but excluding this market, volumes would have increased by 1% [11] - The behavioral segment experienced a headcount growth of 3.1% in Q4 2025, with total same-facility labor expense growth at 7.3% per adjusted day [13] Company Strategy and Development Direction - The company is focused on expanding its inpatient capacity and enhancing outpatient services, with plans to open new facilities in 2026 [5][6] - Investments in technology, including AI, are aimed at improving clinical outcomes and operational efficiency [7][8] - The company is pursuing a disciplined approach to managing expenses while expanding its service offerings to maintain its leadership position [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing investments in people, facilities, and technology [9] - For 2026, the company expects revenue to range between $18.4 billion and $18.8 billion, representing growth of 6%-8% [16] - The guidance assumes same-facility volume growth of 2%-3% for both segments, although initial quarters may be below this range due to winter storms [17] Other Important Information - The company repurchased 4.65 million shares at a total cost of $899 million in 2025, with $1.425 billion of repurchase authorization remaining [16] - Capital expenditures for 2025 were $1 billion, with a significant portion allocated to new hospital projects [15] Q&A Session Summary Question: Guidance for 2026 volume growth and pricing assumptions - Management expects a 3%-4% pricing increase in acute care and 2%-3% in behavioral health, acknowledging a moderation in pricing compared to previous years [23][24] Question: Impact of AI on operating performance - Initial AI efforts focus on administrative efficiencies, with potential significant impacts on revenue and margins expected over time [25][26] Question: Acute care volumes and market performance - Surgical volumes in 2025 lagged overall growth slightly, with expectations for similar trends in 2026 [30][31] Question: Exchange volume visibility and potential bad debt - Management anticipates a 25%-30% decline in exchange volumes, with visibility on bad debt expected to improve over the coming months [36][39] Question: California behavioral staffing requirements impact - New staffing regulations will require a different mix of staff, leading to upfront costs but potentially lower ongoing costs once fully staffed [41][44] Question: Medicaid supplemental programs approval status - Florida's program is expected to be approved soon, while California's program faces more uncertainty [66][70]